Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
US12258329B2 · kind B2 · utility
0Cited by
6References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2019 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Jan 27, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.